Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Pipeline Review, H2 2018
Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Pipeline Review, H2 2018
SUMMARY
According to the recently published report 'Tumor Necrosis Factor Receptor Superfamily Member 6 - Pipeline Review, H2 2018'; Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) pipeline Target constitutes close to 5 molecules.
Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Tumor necrosis factor receptor superfamily member 6 (TNFRSF6) is a protein encoded by the TNFRSF6 gene. It acts as a receptor for TNFSF6/FASLG. The adapter molecule FADD recruits caspase-8 to the activated receptor. FAS-mediated apoptosis plays an important role in the induction of peripheral tolerance in the antigen-stimulated suicide of mature T-cells.
The report 'Tumor Necrosis Factor Receptor Superfamily Member 6 - Pipeline Review, H2 2018' outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 1 and 3 respectively.
Report covers products from therapy areas Oncology, Ophthalmology, Central Nervous System, Dermatology, Immunology and Infectious Disease which include indications Retinal Pigment Epithelial (RPE) Detachment, Actinic (Solar) Keratosis, Autoimmune Disorders, Chronic Lymphocytic Leukemia (CLL), Dry (Atrophic) Macular Degeneration, Genital Warts (Condylomata Acuminata), Lymphoma, Metastatic Breast Cancer, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Ovarian Cancer, Warts and Wet (Neovascular/Exudative) Macular Degeneration.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Tumor Necrosis Factor Receptor Superfamily Member 6 - Pipeline Review, H2 2018'; Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) pipeline Target constitutes close to 5 molecules.
Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Tumor necrosis factor receptor superfamily member 6 (TNFRSF6) is a protein encoded by the TNFRSF6 gene. It acts as a receptor for TNFSF6/FASLG. The adapter molecule FADD recruits caspase-8 to the activated receptor. FAS-mediated apoptosis plays an important role in the induction of peripheral tolerance in the antigen-stimulated suicide of mature T-cells.
The report 'Tumor Necrosis Factor Receptor Superfamily Member 6 - Pipeline Review, H2 2018' outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II and Preclinical stages are 1, 1 and 3 respectively.
Report covers products from therapy areas Oncology, Ophthalmology, Central Nervous System, Dermatology, Immunology and Infectious Disease which include indications Retinal Pigment Epithelial (RPE) Detachment, Actinic (Solar) Keratosis, Autoimmune Disorders, Chronic Lymphocytic Leukemia (CLL), Dry (Atrophic) Macular Degeneration, Genital Warts (Condylomata Acuminata), Lymphoma, Metastatic Breast Cancer, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Ovarian Cancer, Warts and Wet (Neovascular/Exudative) Macular Degeneration.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS)
- The report reviews Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Overview
Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Companies Involved in Therapeutics Development
Baliopharm AG
G&E Corp
Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Drug Profiles
APO-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Novotarg - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONL-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONL-1204 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRT-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Dormant Products
Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Product Development Milestones
Featured News & Press Releases
May 17, 2018: Medical Prognosis Institute and Oncology Venture Announces Abstract On Multiple Myeloma Drug Candidate APO010 at 2018 ASCO clinical meeting
May 31, 2017: MPI's spinout Oncology Venture's second drug candidate in the clinic - First Multiple Myeloma patient in study with APO010, an Immuno-Oncology drug
May 31, 2017: OV‘s second drug candidate in the clinic - First Multiple Myeloma patient in study with APO010, an Immuno-Oncology drug
Mar 28, 2017: ONL Therapeutics Strengthens Leadership With Addition To Board Of Directors And Expansion Of Operations Team
Mar 21, 2017: ONL Therapeutics Receives Nearly $1.0 Million Grant from National Eye Institute for Continued Advancement of ONL1204 Program
Oct 07, 2016: All four Danish centers have started screening Multiple Myeloma patients for OV’s APO010 Study
Aug 19, 2016: Additional two centers started screening of Multiple Myeloma patients in OV’s APO010 Study
Mar 10, 2016: First Patient Included In APO010 Immuno-Oncology Screening Trial By MPI's Spinout Oncology Venture
Feb 11, 2016: ONL Therapeutics Receives Orphan Drug Designation for ONL1204 for Treatment of Retinal Detachment From FDA
Jun 15, 2015: ONL Therapeutics Provides Update on Novel Photoreceptor Protection Platform for Retinal Diseases
May 13, 2015: VCRO Announces Phase II IND Package in Common Technical Document (CTD) Accepted by the USA FDA
Nov 12, 2014: ONL Therapeutics Receives Phase II SBIR Grant From National Eye Institute for Development of Novel Retinal Disease Treatment
Oct 26, 2012: South Africa, first to grant IP protection in anti-warts
May 09, 2012: Baliopharm Signs Licensing Agreement For The Development Of A Bispecific Antibody Indicated For The Treatment Of Cancer And Inflammatory Diseases.
Jan 02, 2012: SR-T100 gel phase III clinical trial was selected as the Center for Drug Evaluation 100 annual cases of major indicators of new drugs
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Overview
Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Companies Involved in Therapeutics Development
Baliopharm AG
G&E Corp
Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Drug Profiles
APO-010 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Novotarg - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONL-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ONL-1204 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SRT-100 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Dormant Products
Tumor Necrosis Factor Receptor Superfamily Member 6 (Apo 1 Antigen or Apoptosis Mediating Surface Antigen FAS or FASLG Receptor or TNFRSF6 or CD95 or FAS) - Product Development Milestones
Featured News & Press Releases
May 17, 2018: Medical Prognosis Institute and Oncology Venture Announces Abstract On Multiple Myeloma Drug Candidate APO010 at 2018 ASCO clinical meeting
May 31, 2017: MPI's spinout Oncology Venture's second drug candidate in the clinic - First Multiple Myeloma patient in study with APO010, an Immuno-Oncology drug
May 31, 2017: OV‘s second drug candidate in the clinic - First Multiple Myeloma patient in study with APO010, an Immuno-Oncology drug
Mar 28, 2017: ONL Therapeutics Strengthens Leadership With Addition To Board Of Directors And Expansion Of Operations Team
Mar 21, 2017: ONL Therapeutics Receives Nearly $1.0 Million Grant from National Eye Institute for Continued Advancement of ONL1204 Program
Oct 07, 2016: All four Danish centers have started screening Multiple Myeloma patients for OV’s APO010 Study
Aug 19, 2016: Additional two centers started screening of Multiple Myeloma patients in OV’s APO010 Study
Mar 10, 2016: First Patient Included In APO010 Immuno-Oncology Screening Trial By MPI's Spinout Oncology Venture
Feb 11, 2016: ONL Therapeutics Receives Orphan Drug Designation for ONL1204 for Treatment of Retinal Detachment From FDA
Jun 15, 2015: ONL Therapeutics Provides Update on Novel Photoreceptor Protection Platform for Retinal Diseases
May 13, 2015: VCRO Announces Phase II IND Package in Common Technical Document (CTD) Accepted by the USA FDA
Nov 12, 2014: ONL Therapeutics Receives Phase II SBIR Grant From National Eye Institute for Development of Novel Retinal Disease Treatment
Oct 26, 2012: South Africa, first to grant IP protection in anti-warts
May 09, 2012: Baliopharm Signs Licensing Agreement For The Development Of A Bispecific Antibody Indicated For The Treatment Of Cancer And Inflammatory Diseases.
Jan 02, 2012: SR-T100 gel phase III clinical trial was selected as the Center for Drug Evaluation 100 annual cases of major indicators of new drugs
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Baliopharm AG, H2 2018
Pipeline by G&E Corp, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Baliopharm AG, H2 2018
Pipeline by G&E Corp, H2 2018
Dormant Products, H2 2018
Dormant Products, H2 2018 (Contd.1), H2 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Baliopharm AG
G&E Corp
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
COMPANIES MENTIONED
Baliopharm AG
G&E Corp
